Oncotype DX Breast DCIS Score - Understanding Your Results
Oncotype DX Breast DCIS Score - Understanding Your Results
Prepare for your appointment with your doctor to review your Oncotype DX Breast DCIS Score results
Oncotype DX Breast DCIS Score - What to Expect
Oncotype DX Breast DCIS Score - What to Expect
Learn more about the Oncotype DX DCIS Score test and why your doctor ordered the test for you.
Do you know your Oncotype DX DCIS Score: Jen
Do you know your Oncotype DX DCIS Score: Jen
Meet Jen - Oncotype DX DCIS Score 42.
Oncotype DX DCIS Breast Cancer Score: Amy's Story
Oncotype DX DCIS Breast Cancer Score: Amy's Story
Amy, a breast cancer survivor, describes her experience using the Oncotype DX Breast DCIS Score to personalize her treatment options. Share this video with your loved ones to...
A Pathologist's Perspective on Using Comprehensive Genomic Profiling to Enhance Patient Care
A Pathologist's Perspective on Using Comprehensive Genomic Profiling to Enhance Patient Care
In this presentation, Drs. Rick Baehner and Joshua Routh will discuss the growing importance of genomic profiling to augment pathologic classification, and the positive impact...
Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling
Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling
USCAP 2021 Oncotype MAP Pan-Cancer Tissue Test Symposium, presented by Rick Baehner, MD and Joshua Routh, MD.
Lab Week Pathology Webinar with Drs. Rick Baehner and Josh Routh
Lab Week Pathology Webinar with Drs. Rick Baehner and Josh Routh
Learn about the Oncotype MAP Pan-Cancer Tissue test from a Pathologist’s Perspective.
Overview of the Oncotype MAP Pan-Cancer Tissue Test
Overview of the Oncotype MAP Pan-Cancer Tissue Test
The Oncotype MAP Pan-Cancer Tissue test is now available through Exact Sciences. This comprehensive test can aid timely therapy selection for advanced cancer patients by providing...
Overview of the Oncotype MAP Test for Pathologists
Overview of the Oncotype MAP Test for Pathologists
TAILORx: Transforming the Treatment of Breast Cancer
TAILORx: Transforming the Treatment of Breast Cancer
Landmark TAILORx results, published on June 3rd, 2018, in the New England Journal of Medicine, demonstrate the Oncotype DX Breast Recurrence Score test definitively Identifies...
Data Supporting Oncotype DX Test: TAILORx Trial
Data Supporting Oncotype DX Test: TAILORx Trial
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak on the results of the landmark TAILORx trial, and how the data guides treatment decisions for their breast...
Using Oncotype DX Test in Management of Node-Positive Breast Cancer
Using Oncotype DX Test in Management of Node-Positive Breast Cancer
Dr. Jeremy Force, Professor of Breast Surgical Oncology at MD Anderson Cancer Center, speaks on value of the use of Oncotype DX Breast Recurrence Score test in node-positive...
Do you know your Oncotype DX Recurrence Score: Lynda
Do you know your Oncotype DX Recurrence Score: Lynda
Meet Lynda - Oncotype DX Recurrence Score 5.
Do You Know Your Oncotype DX Recurrence Score? - Mike
Do You Know Your Oncotype DX Recurrence Score? - Mike
Conoce a Mike - Oncotype DX Recurrence Score 3.
Do you know your Oncotype DX Recurrence Score: Susan
Do you know your Oncotype DX Recurrence Score: Susan
Meet Susan - Oncotype DX Recurrence Score 31.
Not All Breast Cancer Is The Same. Get Your Oncotype DX Recurrence Score
Not All Breast Cancer Is The Same. Get Your Oncotype DX Recurrence Score
Not all breast cancer is the same. Get your Oncotype DX score before you make your treatment decision.
Do you know your Oncotype DX Recurrence Score: Angela
Do you know your Oncotype DX Recurrence Score: Angela
Meet Angela - Oncotype DX Recurrence Score 22.
Do you know your Oncotype DX Recurrence Score: Coree
Do you know your Oncotype DX Recurrence Score: Coree
Meet Coree - Oncotype DX Recurrence Score 13.
Do you know your Oncotype DX Recurrence Score: Katherine
Do you know your Oncotype DX Recurrence Score: Katherine
Meet Katherine - Oncotype DX Recurrence Score 18.
Reggie Shares His Experience with His Wife's Breast Cancer and Oncotype DX Score
Reggie Shares His Experience with His Wife's Breast Cancer and Oncotype DX Score
Not all breast cancer is the same. Get your Oncotype DX score before you make your treatment decision. Diane's husband talks about his experience.
Oncotype DX Breast Recurrence Score Test - What to Expect
Oncotype DX Breast Recurrence Score Test - What to Expect
Learn more about the Oncotype DX Breast Recurrence Score test and why your doctor ordered the test for you.
Understanding the Oncotype DX Results
Understanding the Oncotype DX Results
Prepare for your appointment with your doctor to review your Oncotype DX Breast Recurrence Score results
Managing Breast Cancer During the COVID-19 Pandemic with the Oncotype DX Breast Recurrence Score® Test
Managing Breast Cancer During the COVID-19 Pandemic with the Oncotype DX Breast Recurrence Score® Test
Featuring speakers Christy Russell, MD (Sr. Medical Director, US Oncology) and Rick Baehner, MD (Chief Medical Officer, Precision Oncology).
Applying RxPONDER to Clinical Practice: Miami Breast Cancer Conference 2021 Product Theater
Applying RxPONDER to Clinical Practice: Miami Breast Cancer Conference 2021 Product Theater
At the 2021 Miami Breast Cancer Conference, Drs. Tari King and Kathy Miller discuss lymph node-positive breast cancer cases with Dr. Christy Russell.
Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test
Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test
SABCS 2020 Virtual Product Theatre with speakers: Jeremy Force, DO; Alison Stopeck, MD; and Christy Russell, MD.
Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test
Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test
Dr. Christy Russell, Senior Director of Medical Affairs at Exact Sciences, reviews data that were presented at SABCS 2020 "Enhancing the Utility of the Oncotype DX Breast Recurrence...
Using Oncotype DX Test to Change Management of Early-Stage Breast Cancer
Using Oncotype DX Test to Change Management of Early-Stage Breast Cancer
Dr. Jeremy Force, Dr. Virgina Kaklamani, and Dr. Anthony Lucci speak on how the Oncotype DX Breast Recurrence Score test has changed the management of early-stage breast cancer...
Oncotype DX® Colon Cancer Patient Experience: Interview with Dan C.
Oncotype DX® Colon Cancer Patient Experience: Interview with Dan C.
Dan was diagnosed with stage-II colon cancer. After his tumor was assessed with Genomic Health's Oncotype DX Colon Recurrence Score, he and his doctor were able to create an individualized...
Oncotype DX Genomic Prostate Score Test -- What to Expect
Oncotype DX Genomic Prostate Score Test -- What to Expect
Learn more about the Oncotype DX GPS test and why your doctor ordered the test for you.
Data supporting the Oncotype DX GPS test in racially diverse populations
Data supporting the Oncotype DX GPS test in racially diverse populations
African-American men are more likely to be diagnosed with prostate cancer than European American men. The Oncotype DX GPS test can help make more informed treatment decisions and...
Prostate cancer case study with the Oncotype DX GPS™ test
Prostate cancer case study with the Oncotype DX GPS™ test
See how the Oncotype DX Genomic Prostate Score® test revealed aggressive tumor biology for a patient who initially seemed like a strong candidate for active surveillance.
mpMRI and the Genomic Prostate Score™ Assay
mpMRI and the Genomic Prostate Score™ Assay
For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology...
A Urologist's Experience with Oncotype DX GPS
A Urologist's Experience with Oncotype DX GPS
Ketan Badani, MD teaches and practices urology at Mount Sinai. Hear how the Oncotype DX GPS test helps him feel much more confident in treatment option discussions with patients.
Lloyd and His Wife Discuss Prostate Cancer Treatments
Lloyd and His Wife Discuss Prostate Cancer Treatments
When it comes to prostate cancer, communication is vital, not only with a patient's doctor, but with their partner as well. We join Lloyd and his wife as they, with the help of...
Your Prostate, Your Decision: A Wife's Perspective
Your Prostate, Your Decision: A Wife's Perspective
A prostate cancer patient and his wife share their story to raise awareness that men need to get all the facts before choosing surgery after receiving a prostate cancer diagnosis.
Jim's Story
Jim's Story
Do you know your Oncotype DX Genomic Prostate Score result? Watch Jim tell his prostate cancer story.
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Your Oncotype DX Genomic Prostate score will arm you with information that'll help you take charge of your cancer treatment decision with confidence.
Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer
Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer
See how men with unfavorable intermediate-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the Genomic Prostate Score...
How do you use the GPS™ report? The value of the GPS™ assay.
How do you use the GPS™ report? The value of the GPS™ assay.
Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS™ report in his practice.
For patients with clinically low-risk prostate cancer (very...
How do you use the short-term GPS™ report endpoint, Adverse Pathology?
How do you use the short-term GPS™ report endpoint, Adverse Pathology?
Doctors Scott Sellinger (Advanced Urology Institute) and Brian Helfand (NorthShore Medical Group) explain why adverse pathology is important in helping patients decide next steps...
Oncotype DX Genomic Prostate Score - Understanding Your Results
Oncotype DX Genomic Prostate Score - Understanding Your Results
Prepare for your appointment with your doctor to review your Oncotype DX Genomic Prostate Score results
AR-V7 Case Study – Chemotherapy
AR-V7 Case Study – Chemotherapy
Learn how one physician decided on chemotherapy after assessing his patient’s AR-V7 status using the Oncotype DX AR-V7 Nucleus Detect test.
AR-V7 Case Study – AR-targeted in M0 CRPC
AR-V7 Case Study – AR-targeted in M0 CRPC
Discover how one practitioner used the Oncotype DX AR-V7 Nucleus Detect® test to determine next steps for an mCRPC patient following failure of an AR-targeted therapy in M0 CPRC.
AR-V7 Case Study – Post chemotherapy AR-targeted therapy
AR-V7 Case Study – Post chemotherapy AR-targeted therapy
Discover how one physician used the Oncotype DX AR-V7 Nucleus Detect test to understand his patient’s AR-V7 status, leading him to confidently choose another AR-targeted therapy...
AR-V7 Case Study – Sequential AR-targeted therapy
AR-V7 Case Study – Sequential AR-targeted therapy
Discover how the Oncotype DX AR-V7 Nucleus Detect test helped a physician decide on sequential AR-targeted therapy for his patient.
Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test
Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test
This webinar explains what metastatic castration-resistant prostate cancer (mCRPC) is and how it is currently treated. In addition it will explain the role of resistance to androgen...
Oncotype DX AR-V7 Nucleus Detect test
Oncotype DX AR-V7 Nucleus Detect test
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect...
How does AR-V7 guide treatment decisions in mCRPC?
How does AR-V7 guide treatment decisions in mCRPC?
Find out how AR-V7 testing helps physicians guide treatment decisions for their mCRPC patients based on easy to interpret results.
How do you define AR-targeted therapy failure?
How do you define AR-targeted therapy failure?
Learn what top physicians look for to help determine AR-targeted therapy failure.
mCRPC treatment management post AR-targeted therapy failure
mCRPC treatment management post AR-targeted therapy failure
Your patient fails an AR-targeted therapy. What's next? Leading physicians share insights into how they determine next treatment.
Sequencing therapies in mCRPC patients
Sequencing therapies in mCRPC patients
Learn what top physicians look for when sequencing therapies in mCRPC patients.
Do you refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)?
Do you refer to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)?
Listen to leading physicians discuss the NCCN guidelines® updates and how they incorporate these into their practices for patient management in mCRPC.
AR-V7 testing in mCRPC: A case study
AR-V7 testing in mCRPC: A case study
A leading physician describes how the AR-V7 Nucleus Detect® test helped him make a personalized treatment decision for his mCRPC patient after the patient failed an AR-targeted...
How do you manage mCRPC patients?
How do you manage mCRPC patients?
Leading physicians share insights into mCRPC disease management and how they navigate the rapidly evolving treatment landscape in advanced prostate cancer.
Oncotype DX Patient Bryce Shares His Metastatic Prostate Cancer Story
Oncotype DX Patient Bryce Shares His Metastatic Prostate Cancer Story
After diagnosed with metastatic prostate cancer at age 44, Bryce took an active role in his care, learning about all his options and tools to guide his treatment, including...